Zobrazeno 1 - 10
of 77
pro vyhledávání: '"Cunlin, Wang"'
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundDysregulated and excessive inflammatory reactions can lead to tissue damage, which is the underlying cause of most human diseases. Menisoxoisoaporphine A (MA), a novel oxoisoaporphine alkaloid, was obtained from Menispermi Rhizoma, a tradit
Externí odkaz:
https://doaj.org/article/b1e03e216b1a4255b0b46491c4ff2fad
Autor:
Hengbang Wang, Yun Yang, Zi Chen, Lei Fu, Min Yu, Lixin Jiang, Cunlin Wang, Lichuang Men, Ilisse Minto, Dajun Yang, Yifan Zhai
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 9, Pp n/a-n/a (2024)
Abstract Olverembatinib (HQP1351) is a BCR‐ABL1 tyrosine kinase inhibitor with promising clinical activity. It is approved in China for the treatment of patients with chronic myeloid leukemia harboring drug‐resistant mutations, such as T315I. In
Externí odkaz:
https://doaj.org/article/ca8b78a08c3d4ee09875562f086c12ce
Autor:
Elias Jabbour, Paul B. Koller, Vivian G. Oehler, Omer H Jamy, Sudipto Mukherjee, Anthony M. Hunter, Maria R. Baer, Joseph T. Beck, Zi Chen, Huanshan Guo, Lei Fu, Lichuang Men, Hengbang Wang, Dajun Yang, Yifan Zhai, Hagop Kantarjian, Lixin Jiang, Cunlin Wang
Publikováno v:
Blood. 140:200-202
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6be9346da781cb6a227095f54703fad7
https://doi.org/10.1182/blood-2022-162387
https://doi.org/10.1182/blood-2022-162387
Publikováno v:
Pharmacoepidemiology and Drug Safety. 29:1213-1218
Following the release of the framework for the Real-World Evidence (RWE) Program, the US Food and Drug Administration (FDA) is actively evaluating and exploring ways to optimize the utility of real-world data (RWD) and RWE to support regulatory decis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e69aac773b4ac9c056b0401ab25931a5
https://doi.org/10.1002/pds.4962
https://doi.org/10.1002/pds.4962
Autor:
Khaled Alamri, Molly L. Aldridge, Larry Alphs, Barbara E. Bierer, Eric P. Borrelli, Jaclyn L.F. Bosco, Nicholas Brooke, Emily S. Brouwer, Aisling R. Caffrey, Alicyn Campbell, Timothy S. Carey, Wendy Camelo Castillo, John Chaplin, Jennifer B. Christian, Thomas W. Concannon, Catherine Copley-Merriman, Kourtney Davis, Robert S. Epstein, Nicolle M. Gatto, Cynthia J. Girman, Rolf H.H. Groenwold, Cynthia Grossman, Kristen A. Hahn, Anne Marie Hamior, Katherine E. Harris, Ehab Hasan, Austin R. Horn, Phyo T. Htoo, Kristy Iglay, Michele Jonsson Funk, Sylvia Baedorf Kassis, Bray Patrick Lake, Suzanne N. Landi, Craig Lipset, Vincent Lo Re, Jennifer L. Lund, Kenneth Man, Elizabeth Manning, Leah McGrath, Michelle Medeiros, Marilyn A. Metcalf, Margaret Mordin, Mary Stober Murray, Nabil Natafgi, Catherine A. Panozzo, Jeanne M. Pimenta, Sudha R. Raman, Jeanne M. Regnante, Nicole A. Richie, Mary E. Ritchey, Jamie Roberts, Ify Sargeant, Roslyn F. Schneider, Suzanne Schrandt, Joe V. Selby, Soko Setoguchi, Ju-Young (Judy) Shin, Joanna Siegel, Fabian Somers, Komathi Stem, Til Stürmer, Elizabeth A. Suarez, J. Russell Teagarden, Kevin E. Thorpe, Lina Titievsky, Andrea B. Troxel, Priscilla Velentgas, Cunlin Wang, Jenna Wong, Stephen Yates, Guy Yeoman, Wei Zhou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfe115e0e1fb3d212f5d186895ac3cf3
https://doi.org/10.1016/b978-0-12-817663-4.01002-3
https://doi.org/10.1016/b978-0-12-817663-4.01002-3
The needs for rare disease research and orphan drug development have been increasingly recognized in the last few decades, partly due to legislative change, providing incentives for new treatments of rare disease. There are several unique challenges
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a1adae162a5947f650ff33d4f8b7314
https://doi.org/10.1016/b978-0-12-817663-4.00010-6
https://doi.org/10.1016/b978-0-12-817663-4.00010-6
Autor:
Angel Qin, Gregory Peter Kalemkerian, Nisha Anjali Mohindra, Jyoti D. Patel, Christos Stelios Karapetis, Jennifer W Carlisle, Jacob Sands, Alexander I. Spira, Bo Gao, Harshad Amin, Bishnuhari Paudyal, Genevieve Frank, Xuemei Sun, Yang Xu, Cunlin Wang, Tommy Fu, Robert Winkler, Zhiyan Liang, Dajun Yang, Yifan Zhai
Publikováno v:
Journal of Clinical Oncology. 40:e20612-e20612
e20612 Background: Targeting BCL-2/BCL-xL proteins is considered an important approach for anticancer drug development. Investigational pelcitoclax (APG-1252) as a single agent is a novel BCL-2/BCL-xL dual inhibitor, which has demonstrated synergisti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b490be150a28ce5e5117d11851028eb
https://doi.org/10.1200/jco.2022.40.16_suppl.e20612
https://doi.org/10.1200/jco.2022.40.16_suppl.e20612
Autor:
Tommy Fu, Ming Lu, Piyush Sheladia, Eric Liang, Srdan Verstovsek, Yifan Zhai, Cunlin Wang, Dajun Yang, Sasha McClain, Boyd Mudenda, Naveen Pemmaraju, Jiao Ji
Publikováno v:
Blood. 136:15-16
Background: Pelcitoclax (APG-1252), a novel dual inhibitor of Bcl-2/Bcl-xL, is active as monotherapy in patients with advanced solid tumors and well tolerated up to 240 mg twice weekly (NCT03387332). Preclinical data suggest that cells with Janus-ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b84617ee32dea51e14a59ed1c81d30b8
https://doi.org/10.1182/blood-2020-137260
https://doi.org/10.1182/blood-2020-137260
Autor:
Cunlin Wang, Zhiyan Liang, Jacob Sands, Nisha Mohindra, Tommy Fu, Dajun Yang, Gregory P. Kalemkerian, Yifan Zhai, Ming Lu, Jyoti D. Patel, Zhicong He, Jennifer W Carlisle, Riccardo Bombelli, Robert Winkler, Vakessa Hammock, Angel Qin, Yang Xu
Publikováno v:
Journal of Clinical Oncology. 39:TPS8589-TPS8589
TPS8589 Background: Increased expression of BCL-2, BCL-xL, and MCL-1 allows certain tumors to evade apoptosis. Pelcitoclax is a novel, dual BCL-2/BCL-xL inhibitor with strong single-agent antitumor activity against tumor cells addicted to BCL-2, BCL-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b5ec628300de1fd029229de53b664e1
https://doi.org/10.1200/jco.2021.39.15_suppl.tps8589
https://doi.org/10.1200/jco.2021.39.15_suppl.tps8589
Autor:
Jason Chen, Nehal Lakhani, Qi Zeng, Zhiyan Liang, Drew W. Rasco, Lei Fu, Cunlin Wang, Dajun Yang, Ming Lu, Yifan Zhai, Yuefen Tang, Hengbang Wang
Publikováno v:
Journal of Clinical Oncology. 38:3509-3509
3509 Background: Targeting Bcl-2/Bcl-xL proteins is considered as an important approach for anticancer drug development. Palcitoclax (APG-1252) was being developed to reduce on-target platelet toxicity without diminishing antitumor potency. Methods:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f63020ed520a9b412bbef414e4e071b1
https://doi.org/10.1200/jco.2020.38.15_suppl.3509
https://doi.org/10.1200/jco.2020.38.15_suppl.3509